MRTX logo

Mirati Therapeutics (MRTX) Accounts Payable

Annual Accounts Payable

$38.86 M
+$3.70 M+10.52%

December 31, 2022

Summary

Performance

1-Year Change

+10.52%

3-Year Change

+137.44%

5-Year Change

+794.59%

15-Year Change

+794.59%

MRTX Accounts Payable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$38.86 M
MRTX annual accounts payable is currently at an all-time high

3-Year Low

$35.16 M
MRTX annual accounts payable is currently +10.52% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
MRTX previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
MRTX next annual earnings announcement has not yet been scheduled

OtherMRTXbalance sheetmetrics:

Annual Accounts Receivable

$865.00 K
MRTX annual accounts receivable is $865.00 thousand

Annual Total Liabilities

$206.13 M
MRTX annual total liabilities is $206.13 million

Annual Total Assets

$1.20 B
MRTX annual total assets is $1.20 billion

Annual Current Assets

$1.11 B
MRTX annual total current assets is $1.11 billion

Quarterly Accounts Payable

$37.96 M
+$5.45 M+16.78%

September 30, 2023

Summary

Performance

3-Month Change

+16.78%

1-Year Change

+95.15%

3-Year Change

+137.63%

5-Year Change

+454.74%

MRTX Quarterly Accounts Payable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$42.92 M
MRTX quarterly accounts payable is currently -11.56% below its historical high of $42.92 million

3-Year Low

$19.45 M
MRTX quarterly accounts payable is currently +95.15% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
MRTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
MRTX next earnings announcement has not yet been scheduled

OtherMRTXbalance sheetmetrics:

Quarterly Accounts Receivable

$14.65 M
MRTX quarterly accounts receivable is $14.65 million

Quarterly Total Liabilities

$183.24 M
MRTX quarterly total liabilities is $183.24 million

Quarterly Total Assets

$1.13 B
MRTX quarterly total assets is $1.13 billion

Quarterly Current Assets

$1.04 B
MRTX quarterly total current assets is $1.04 billion

Accounts Payable Formula

Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers

MRTX Accounts Payable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+10.5%+95.2%
3 y3 years+137.4%+137.6%
5 y5 years+794.6%+454.7%

MRTX Accounts Payable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high-9.5%-2.3%-48.8%
5 y5-yearat high-57.9%-11.6%-74.7%
alltimeall timeat high-98.0%-11.6%-98.6%

Mirati Therapeutics Accounts Payable History

DateAnnualQuarterly
Sep 2023
-
$37.96 M(+16.8%)
Jun 2023
-
$32.51 M(+45.6%)
Mar 2023
-
$22.32 M(-42.6%)
Dec 2022
$38.86 M(+10.5%)
$38.86 M(+99.8%)
Sep 2022
-
$19.45 M(-19.8%)
Jun 2022
-
$24.27 M(-13.1%)
Mar 2022
-
$27.94 M(-20.5%)
Dec 2021
$35.16 M(+94.1%)
$35.16 M(-18.1%)
Sep 2021
-
$42.92 M(+79.8%)
Jun 2021
-
$23.87 M(+21.8%)
Mar 2021
-
$19.60 M(+8.2%)
Dec 2020
$18.12 M(+10.7%)
$18.12 M(+13.4%)
Sep 2020
-
$15.97 M(-33.7%)
Jun 2020
-
$24.10 M(+151.4%)
Mar 2020
-
$9.59 M(-41.4%)
Dec 2019
$16.37 M(+91.9%)
$16.37 M(+30.2%)
Sep 2019
-
$12.57 M(+19.6%)
Jun 2019
-
$10.51 M(+4.4%)
Mar 2019
-
$10.07 M(+18.0%)
Dec 2018
$8.53 M(+96.4%)
$8.53 M(+24.7%)
Sep 2018
-
$6.84 M(+60.4%)
Jun 2018
-
$4.27 M(-9.8%)
Mar 2018
-
$4.73 M(+8.9%)
Dec 2017
$4.34 M(-31.0%)
$4.34 M(+59.2%)
Sep 2017
-
$2.73 M(-31.3%)
Jun 2017
-
$3.97 M(+15.2%)
Mar 2017
-
$3.45 M(-45.2%)
Dec 2016
$6.30 M
$6.30 M(+96.1%)
Sep 2016
-
$3.21 M(-27.8%)
Jun 2016
-
$4.45 M(+37.4%)
DateAnnualQuarterly
Mar 2016
-
$3.24 M(+53.8%)
Dec 2015
$2.10 M(+27.1%)
$2.10 M(-35.2%)
Sep 2015
-
$3.25 M(+79.2%)
Jun 2015
-
$1.81 M(+42.6%)
Mar 2015
-
$1.27 M(-23.2%)
Dec 2014
$1.66 M(+27.1%)
$1.66 M(-14.4%)
Sep 2014
-
$1.93 M(+100.8%)
Jun 2014
-
$963.00 K(+76.4%)
Mar 2014
-
$546.00 K(-58.1%)
Dec 2013
$1.30 M(-25.7%)
$1.30 M(-34.9%)
Sep 2013
-
$2.00 M(+42.4%)
Jun 2013
-
$1.41 M(+17.4%)
Mar 2013
-
$1.20 M(-31.7%)
Dec 2012
$1.75 M(+129.6%)
$1.75 M(+129.6%)
Dec 2011
$763.00 K(-82.5%)
$763.00 K(-89.7%)
Sep 2008
-
$7.38 M(-7.7%)
Jun 2008
-
$7.99 M(+7.3%)
Mar 2008
-
$7.44 M(+14.5%)
Sep 2007
-
$6.50 M(+54.5%)
Jun 2007
-
$4.21 M(+14.3%)
Mar 2007
-
$3.68 M(-15.4%)
Dec 2006
$4.35 M(+30.8%)
$4.35 M(+30.2%)
Sep 2006
-
$3.34 M(+11.6%)
Jun 2006
-
$3.00 M(+4.3%)
Mar 2006
-
$2.87 M(-13.6%)
Dec 2005
$3.33 M(+42.0%)
$3.33 M(+21.2%)
Sep 2005
-
$2.75 M(+16.5%)
Jun 2005
-
$2.36 M(+4.5%)
Mar 2005
-
$2.26 M
Dec 2004
$2.34 M
-

FAQ

  • What is Mirati Therapeutics annual accounts payable?
  • What is the all time high annual accounts payable for Mirati Therapeutics?
  • What is Mirati Therapeutics annual accounts payable year-on-year change?
  • What is Mirati Therapeutics quarterly accounts payable?
  • What is the all time high quarterly accounts payable for Mirati Therapeutics?
  • What is Mirati Therapeutics quarterly accounts payable year-on-year change?

What is Mirati Therapeutics annual accounts payable?

The current annual accounts payable of MRTX is $38.86 M

What is the all time high annual accounts payable for Mirati Therapeutics?

Mirati Therapeutics all-time high annual accounts payable is $38.86 M

What is Mirati Therapeutics annual accounts payable year-on-year change?

Over the past year, MRTX annual accounts payable has changed by +$3.70 M (+10.52%)

What is Mirati Therapeutics quarterly accounts payable?

The current quarterly accounts payable of MRTX is $37.96 M

What is the all time high quarterly accounts payable for Mirati Therapeutics?

Mirati Therapeutics all-time high quarterly accounts payable is $42.92 M

What is Mirati Therapeutics quarterly accounts payable year-on-year change?

Over the past year, MRTX quarterly accounts payable has changed by +$18.51 M (+95.15%)